Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
24 May 2013: “A catastrophic threat” is what the Chief Medical Officer for England, Professor Dame Sally Davies, called the worrying increase in antibiotic-resistant bacteria in her Annual Report. “If we don’t act now, any one of us could go into hospital in 20 years for minor surgery and die because of an ordinary infection that can’t be treated by antibiotics”. The Report received a lot of coverage in the media, including TV and radio appearances from TranScrip Partners.
In the BBC File on 4 programme broadcast on Tuesday, 21 May 2013 (to be repeated on Sunday 26th May) Alan Urry interviewed physicians on the front line of microbiology and infectious diseases, Dame Sally Davies, and the drug development expert Dr. Richard Bax from TranScrip Partners. Whilst the discussion focused on the issue of monitoring resistance and controlling antibiotic use (both extremely valuable measures), little was mentioned regarding the recent recognition that controlling antibiotic use cannot be the sole means of avoiding the emergence of superbugs. The frightening aspect of the crisis is that there is mounting evidence that whilst we can dramatically reduce the spread of resistant organisms such as MRSA and Clostridium difficile, we cannot eradicate them. The lack of new antibiotics to combat the resistant organisms is so great that UK, European and US governments have initiated both public and private partnership investments. The have also encouraged special approaches to regulation of the development of antibiotics to incentivise academic researchers, biotech companies and big pharma to look for different types of antibiotics rather than the limited classes of drugs we have available now. Given the threat of bacterial resistance the need for truly new antibiotics is pressing.
Richard Bax, who was involved in the development of almost all classes of antibiotics over the past 30 years, commented that “The need for new antibiotics is seriously pressing and through TranScrip we are strongly involved in both public and private initiatives to support this.”
TranScrip Partners supports biopharmaceutical product development and life-cycle management across a client base of over 80 companies. TranScrip Partners challenges the traditional CRO model by offering to clients both top-level therapeutic expertise in overcoming the hurdles encountered from translational medicine to successful registration and market access and the staff to support the projects. Services offered by TranScrip Partners include development and market positioning strategies for early molecules as well as tailored support in drug development, medical affairs, pharmacovigilance, regulatory and medical writing during pre and post-approval.
For more information, contact Gina Wessels, Marketing Director, TranScrip Partners on +44 (0) 7557 235 030 or e-mail: firstname.lastname@example.org
For media enquiries, please contact Tristan Jervis on +44 (0) 207 203 6740 or e-mail: email@example.com.
Help employers find you! Check out all the jobs and post your resume.